Midregional pro-atrial natriuretic peptide in the general population

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 5, 2013, Pages 1125-1133

  Tzikas, Stergios ^a   Keller, Till ^b,c   Wild, Philipp S ^a   Schulz, Andreas ^a   Zwiener, Isabella ^a   Zeller, Tanja ^c   Schnabel, Renate B ^c   Sinning, Christoph ^c   Lubos, Edith ^c   Kunde, Jan ^d   Münzel, Thomas ^a   Lackner, Karl J ^a   Blankenberg, Stefan ^c  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

^d THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

Correlations; Distribution; General population; MR proANP; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; MIDREGIONAL PRO ATRIAL NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DYSLIPIDEMIA; FEMALE; FUNCTION TEST KIT; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; KIDNEY FUNCTION; LATEX PARTICLE ENHANCED IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SMOKING;

ADULT; AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED;

EID: 84882263454     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0541     Document Type: Article

References (25)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
2. Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012;33:2001-6.
3. Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
4. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.
5. Ala-Kopsala M, Magga J, Peuhkurinen K, Leip ä l ä J, Ruskoaho H, Leppäluoto J, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of Aand B-type natriuretic peptides. Clin Chem 2004;50:1576-88.
6. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:234-6.
7. Katan M, Fluri F, Schuetz P, Morgenthaler NG, Zweifel C, Bingisser R, et al. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol 2010;56:1045-53.
8. Wild PS, Sinning CR, Roth A, Wilde S, Schnabel RB, Lubos E, et al. Distribution and categorization of left ventricular measurements in the general population: results from the population-based Gutenberg Heart Study. Circ Cardiovasc Imaging 2010;3:604-13.
9. Després J-P, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008;28:1039-49.
10. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-72.
11. Solberg HE. International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values, and International Committee for Standardization in Haematology (ICSH), Standing Committee on Reference Values. Approved Recommendation (1986) on the theory of reference values. Part
12. The concept of reference values. J Clin Chem Clin Biochem 1987;25:337-42.
13. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-62.
14. Maisel A, Mueller C, Adams K Jr., Anker SD, Aspromonte N, Cleland JG, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824-39.
15. Pandey KN. Kinetic analysis of internalization, recycling and redistribution of atrial natriuretic factor-receptor complex in cultured vascular smooth-muscle cells. Ligand-dependent receptor down-regulation. Biochem J 1992;288:55-61.
16. Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, et al. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: The MMKD Study. Kidney Int 2009;75:408-14.
17. Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, et al. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: The LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2008;51:1857-64.
18. Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010;12:338-47.
19. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-76.
20. Maisel A, Neath SX, Landsberg J, Mueller C, Nowak RM, Peacock WF, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail 2012;14:278-86.
21. Bhandari SS, Davies JE, Struck J, Ng LL. Influence of confounding factors on plasma mid-regional pro-adrenomedullin and mid-regional pro-a-type natriuretic peptide concentrations in healthy individuals. Biomarkers 2011;16:281-7.
22. Daniels LB, Clopton P, Potocki M, Mueller C, McCord J, Richards M, et al. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail 2012;14:22-31.
23. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction.
24. Alpert JS, White HD, Biomarker Group, Jaffe AS, Apple FS, et al. Universal definition of myocardial infarction: Kristian Thygesen.
25. Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Eur Heart J 2007;28:2525-38.